Overview

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
This is a study to assess the efficacy and safety of 8 weeks of treatment with Dexlansoprazole modified release (MR)(60 mg daily and 90 mg daily) compared to Lansoprazole (30 mg daily) in healing subjects with endoscopically proven erosive esophagitis.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Treatments:
Dexlansoprazole
Lansoprazole